IMR Press / RCM / Volume 23 / Issue 11 / DOI: 10.31083/j.rcm2311370
Open Access Review
Recent Evidence on Advances in PCI Treatment for Left Main Coronary Artery Disease
Show Less
1 Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 200235 Shanghai, China
*Correspondence: (Chengxing Shen)
Academic Editors: George Dangas and Christian Hengstenberg
Rev. Cardiovasc. Med. 2022, 23(11), 370;
Submitted: 29 March 2022 | Revised: 3 August 2022 | Accepted: 16 August 2022 | Published: 31 October 2022
(This article belongs to the Special Issue Recent Advances in Percutaneous Coronary Intervention)
Copyright: © 2022 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Revascularization therapy significantly improves the outcomes of patients with left main coronary artery disease (LMCAD), compared with medical therapy alone. For many years, coronary artery bypass grafting (CABG) has been the primary and standard treatment strategy. However, with advances in percutaneous coronary intervention (PCI) techniques and improvements in patients’ outcomes, there is growing evidence supporting PCI for LMCAD. In this review, we aim to integrate the available evidences on advances in PCI treatment for LMCAD and provide guidance for further clinical practice.

left main coronary artery disease
percutaneous coronary intervention
coronary artery bypass grafting
Back to top